Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Dragonfly Therapeutics
Exelixis
Xencor, Inc.
ViroMissile, Inc.
Arcus Biosciences, Inc.
Pfizer
Tizona Therapeutics, Inc
Novartis
Shanghai Henlius Biotech
Poseida Therapeutics, Inc.
Werewolf Therapeutics, Inc.
MacroGenics
City of Hope Medical Center
Novartis
Bayer
Kura Oncology, Inc.
Calico Life Sciences LLC
GlaxoSmithKline
Sairopa B.V.
Bristol-Myers Squibb
NeoTX Therapeutics Ltd.
LG Chem
HiFiBiO Therapeutics
HiFiBiO Therapeutics
Bolt Biotherapeutics, Inc.
Coherus Oncology, Inc.
AbbVie
Nanobiotix
Incyte Corporation
Actym Therapeutics, Inc.
Janux Therapeutics
Chongqing Precision Biotech Co., Ltd
Sichuan Baili Pharmaceutical Co., Ltd.
Novelty Nobility, Inc.
Pfizer
Asher Biotherapeutics, Inc.
Pfizer
Exelixis
Xencor, Inc.
Incyte Corporation
NextPoint Therapeutics, Inc.
Shanghai Junshi Bioscience Co., Ltd.
Thomas Jefferson University
University of California, Davis
Turnstone Biologics, Corp.
Checkpoint Therapeutics, Inc.
Sotio Biotech Inc.
Novartis
Eli Lilly and Company